PDL BioPharma Inc (PDLI)

2.20
0.12 5.77
NASDAQ : Health Care
Prev Close 2.08
Open 2.09
Day Low/High 2.06 / 2.22
52 Wk Low/High 2.58 / 6.20
Volume 2.26M
Avg Volume 2.15M
Exchange NASDAQ
Shares Outstanding 165.54M
Market Cap 344.32M
EPS 2.00
P/E Ratio 1.94
Div & Yield 0.20 (9.60%)

Latest News

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Short Interest In PDL BioPharma Declines 14.2%

Short Interest In PDL BioPharma Declines 14.2%

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,140,664 share decrease in total short interest for PDL BioPharma Inc , to 6,915,394, a decrease of 14.16% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 28% Lower For PDLI

Short Interest Moves 28% Lower For PDLI

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 3,055,374 share decrease in total short interest for PDL BioPharma Inc , to 7,833,748, a decrease of 28.06% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Following Thursday's closing bell, PDL BioPharma (PDLI) reported lower-than-expected revenue for the 2016 second quarter.

Dividend Action Aplenty This Week

Earnings season is often a busy period for dividend hikes and cuts, and this one has been no exception.

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)

Trade-Ideas LLC identified PDL BioPharma (PDLI) as a weak on high relative volume candidate

First Week of PDLI February 2017 Options Trading

First Week of PDLI February 2017 Options Trading

Investors in PDL BioPharma Inc saw new options become available this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

This Stock Has A 5.79% Yield, Sells For Less Than Book, and Insiders Have Been Buying

This Stock Has A 5.79% Yield, Sells For Less Than Book, and Insiders Have Been Buying

In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view of the business, and presumably the only reason an insider would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both.

PDL BioPharma (PDLI): Today's Weak On High Volume Stock

PDL BioPharma (PDLI): Today's Weak On High Volume Stock

Trade-Ideas LLC identified PDL BioPharma (PDLI) as a weak on high relative volume candidate

PDL BioPharma About To Put More Money In Your Pocket (PDLI)

PDL BioPharma About To Put More Money In Your Pocket (PDLI)

Looking at the universe of stocks we cover at Dividend Channel, on 6/2/16, PDL BioPharma Inc will trade ex-dividend, for its quarterly dividend of $0.05, payable on 6/13/16. As a percentage of PDLI's recent stock price of $3.36, this dividend works out to approximately 1.49%, so look for shares of PDL BioPharma Inc to trade 1.49% lower — all else being equal — when PDLI shares open for trading on 6/2/16.

3 Small Biotechs That Look Very Healthy

Peter Lynch and other market legends would love these names.

Insiders Bullish on Certain Holdings of DES

Insiders Bullish on Certain Holdings of DES

A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund (DES) shows an impressive 17.3% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » PDL BioPharma Inc , which makes up 0.49% of the WisdomTree SmallCap Dividend Fund (DES), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.

Commit To Purchase PDL BioPharma At $3, Earn 17.2% Annualized Using Options

Commit To Purchase PDL BioPharma At $3, Earn 17.2% Annualized Using Options

Investors considering a purchase of PDL BioPharma Inc shares, but tentative about paying the going market price of $3.73/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $3 strike, which has a bid at the time of this writing of 30 cents.

PDL BioPharma (PDLI) Strong On High Relative Volume Today

PDL BioPharma (PDLI) Strong On High Relative Volume Today

Trade-Ideas LLC identified PDL BioPharma (PDLI) as a strong on high relative volume candidate